Belgium | Phase III | Pulmonary/Respiratory Diseases

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Virtual Booth

Contact Supplier

Check COS database
Check USDMF database

Xls

Filters

FILTER:

Company Name

Year

DEALS // DEV.

Country

Sponsor

Therapeutic Area

Study Phase

Deal Type

Product Type

Dosage Form

Lead Product

Target

Filters

Reset Filter

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Galapagos

Belgium

Boulder Peptide

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Ziritaxestat

Therapeutic Area : Pulmonary/Respiratory Diseases

Study Phase : Phase III

Sponsor : Gilead Sciences

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF

Details : The decision is based on the recommendations of the Independent Data Monitoring Committee (IDMC). Patients continued on their standard of care background treatment and were randomized on to either 200 mg or 600 mg ziritaxestat once daily or placebo.

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 02, 2021